cis-4-amino-1-ethylamino-cyclohexane | 51635-91-7

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: cis-4-amino-1-ethylamino-cyclohexane
• 英文别名: cis-4-amino-1-ethylamino-cyclohexane；cis-4-Amino-1-aethylamino-cyclohexan
• CAS: 51635-91-7
• 化学式: C₈H₁₈N₂
• 分子量: 142.244
• InChiKey: YOJMZMYEUSHGMD-OCAPTIKFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.87
• 重原子数：
  10.0
• 可旋转键数：
  2.0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  38.05
• 氢给体数：
  2.0
• 氢受体数：
  2.0

反应信息

• 作为反应物：
  描述：

  3-(1H-benzimidazol-2-yl)-4-chloro-1H-pyridin-2-one 、 cis-4-amino-1-ethylamino-cyclohexane 在 三乙胺 作用下， 以 乙醇 为溶剂， 反应 1.0h， 生成
  参考文献：
  名称：

  Structure-based design and development of (benz)imidazole pyridones as JAK1-selective kinase inhibitors

  摘要：

  The mammalian Janus Kinases (JAK1, JAK2, JAK3 and TYK2) are intracellular, non-receptor tyrosine kinases whose activities have been associated in the literature and the clinic with a variety of hyperproliferative diseases and immunological disorders. At the onset of the program, it was hypothesized that a JAK1 selective compound over JAK2 could lead to an improved therapeutic index relative to marketed non-selective JAK inhibitors by avoiding the clinical AEs, such as anemia, presumably associated with JAK2 inhibition.During the course of the JAK1 program, a number of diverse chemical scaffolds were identified from both uHTS campaigns and de novo scaffold design. As part of this effort, a (benz)imidazole scaffold evolved via a scaffold-hopping exercise from a mature chemical series. Concurrent crystallography-driven exploration of the ribose pocket and the solvent front led to analogs with optimized kinome and JAK1 selectivities over the JAK2 isoform by targeting several residues unique to JAK1, such as Arg-879 and Glu-966. (C) 2016 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2016.02.035
• 作为产物：
  描述：

  对硝基氯苯 在 1,4-二氧六环 、 钌 作用下， 生成 cis-4-amino-1-ethylamino-cyclohexane
  参考文献：
  名称：

  脂环族二胺的合成。

  摘要：

  DOI：

  10.1021/ja01211a053

文献信息

• [EN] HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF<br/>[FR] COMPOSÉS HÉTÉROARYLES SERVANT D'INHIBITEURS D'IRAK, ET LEURS UTILISATIONS
  申请人：MERCK PATENT GMBH

  公开号：WO2016081679A1

  公开（公告）日：2016-05-26

  The present invention relates to compounds of Formula I or a pharmaceutically acceptable salt thereof, useful as IRAK inhibitors.

  本发明涉及式I化合物或其药用可接受盐，用作IRAK抑制剂。
• FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS
  申请人：Vaccaro Wayne

  公开号：US20080045536A1

  公开（公告）日：2008-02-21

  Compounds having the formula (I), and enantiomers, and diastereomers, pharmaceutically-acceptable salts, thereof, are useful as kinase modulators, including MK2 modulation, wherein one of E and F is a nitrogen atom and the other of E and F is a carbon atom, Z is N or CR 3 , and R 1 , R 2 , R 3 , X and Y are as defined herein.

  具有公式（I）的化合物，其对映异构体，顺反异构体和药学上可接受的盐，对于激酶调节剂是有用的，包括MK2调节剂，其中E和F中的一个是氮原子，另一个是碳原子，Z是N或CR3，而R1，R2，R3，X和Y如此定义。
• US7723336B2
  申请人：——

  公开号：US7723336B2

  公开（公告）日：2010-05-25
• [EN] FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS<br/>[FR] COMPOSES HETEROCYCLIQUES CONDENSES UTILISES COMME MODULATEURS DES KINASES
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2007038314A2

  公开（公告）日：2007-04-05

  [EN] Compounds having the formula (I), and enantiomers, and diastereomers, pharmaceutically-acceptable salts, and hydrates, thereof, (I) are useful as kinase modulators, including MK2 modulation, wherein one of E and F is a nitrogen atom and the other of E and F is a carbon atom, and Z is N or CR₃, and R₁, R₂, R₃, X and Y are as defined herein.
  [FR] L'invention concerne des composés représentés par la formule (I), et des énantiomères, et des diastéréomères, des sels pharmaceutiquement acceptables, et des hydrates de ceux-ci, utilisés comme modulateurs des kinases, notamment pour la modulation de MK2. L'un de E et F représente un atome d'azote, et l'autre représente un atome de carbone, Z représente N ou CR₃, et R₁, R₂, R₃, X et Y sont tels que définis dans le descriptif.